Clinical Takeaway
Cannabis use for anxiety showed daily reductions in anxiety symptoms, but the magnitude and pattern of relief differed depending on whether participants used flower or edible products. THC and CBD combinations, as well as product form, appear to influence how consistently anxiety relief is achieved over time. Patients considering cannabis for anxiety management should understand that product type and delivery method meaningfully affect outcomes, and clinical guidance tailored to these variables is warranted.
#8 Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products.
Citation: Rosa Luiza et al.. Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products.. International journal of environmental research and public health. 2026. PMID: 41752306.
Design: 5 Journal: 0 N: 2 Recency: 3 Pop: 2 Human: 1 Risk: -2
This study provides longitudinal evidence on the differential anxiolytic effects of cannabis flower versus edibles in real-world settings, addressing a critical knowledge gap since most clinical data relies on controlled dosing rather than patient-directed use patterns. Understanding product-specific outcomes is essential for clinical guidance, as patients increasingly self-select cannabis formulations for anxiety management, yet clinicians lack robust data to inform recommendations or identify which populations benefit from particular delivery methods. The daily assessment design captures clinically relevant information about symptom trajectories that cross-sectional or single-dose studies cannot provide, enabling more evidence-based patient counseling on cannabis as an anxiety intervention.
Quality Gate Alerts:
- Preclinical only
Abstract: Research shows that delta-9-tetrahydrocannabinol (THC) is linked to increased anxiety, while cannabidiol (CBD) may have anxiolytic effects. Cannabis use is often driven by coping with anxiety, though its daily impact on anxiety remains unclear. This study examined daily associations between cannabis use and anxiety across 30 days in adults who wanted to use cannabis for anxiety relief. Participants (N = 345) used flower or edible products ad libitum and were randomly assigned to groups by product type (CBD, THC, or THC + CBD). Each day, participants reported cannabis use in the past 24 h and rated their anxiety. Linear mixed-effects models tested whether anxiety changed over time, differed by cannabinoid group, and varied with use. Anxiety significantly decreased over the study period in both flower and edibles groups. In the flower group, THC + CBD and CBD products had greater decreases in anxiety (39.5% and 34.8%, respectively) compared to THC products (7.8%). In the edibles group, when participants used CBD products, this was associated with a 24.9% reduction in anxiety over the 30 days. Findings underscore the importance of distinguishing cannabis effects by product type and cannabinoid composition and suggest that CBD-dominant edibles were associated with less anxiety over time in this naturalistic study.
🧠 This longitudinal study provides useful real-world data suggesting that cannabis product formulation may influence anxiety outcomes, with differential effects observed between flower and edible preparations over a 30-day period. However, several important limitations warrant clinical caution: the study lacks a control group, relies on self-reported anxiety measures without standardized clinical assessment, does not stratify results by THC:CBD ratio or absolute cannabinoid concentrations, and cannot establish whether observed improvements reflect true therapeutic effect versus placebo response or regression to the mean in a self-selected population seeking anxiety relief. The ad libitum dosing design, while ecologically valid, prevents us from determining optimal doses and introduces confounding from individual titration patterns and underlying anxiety severity. Given the well-established association between THC and anxiety exacerbation in some patients, clinicians should remain cautious about recommending cannabis as first-line anxiety treatment and should counsel patients that product type, cannabinoid profile, and individual neurochemistry likely determine whether cannabis will help or worsen their symptoms
| |